ライフサイエンスコーパス: neoadjuvant

1 ith HER2-positive early breast cancer in the neoadjuvant-adjuvant setting.

2 undergoing active anticancer treatment in a neoadjuvant/adjuvant and 560 of 1,016 (55.1%) in a palli

3 We conducted a study of neoadjuvant/adjuvant anti-PD-1 therapy in stage III/IV m

4 These findings suggest that the neoadjuvant administration of PD-1 blockade enhances bot

5 Overall, 1,065 patients were included (531 neoadjuvant and 534 adjuvant).

6 ositive breast cancer treated with different neoadjuvant and adjuvant anti-HER2-based combinations an

7 tery involvement), or treatment factors (eg, neoadjuvant and adjuvant therapy use) differed between t

8 tal arm (14.4% v 37.3% and 23.4% v 46.6% for neoadjuvant and adjuvant treatment, respectively).

9 ntigen < 30 ng/mL were randomly allocated to neoadjuvant and concurrent ADT for 6 months starting 4 m

10 On the basis of these results, both neoadjuvant and concurrent initiations of short-term ADT

11 s in the imatinib era who received imatinib (neoadjuvant and/or adjuvant) had higher risk tumors, but

12 Neoadjuvant anti-PD-1 treatment is effective in high-ris

13 trials offering comparison with the emerging neoadjuvant approach are lacking.

14 ubgroup analyses suggest an advantage of the neoadjuvant approach, additional evidence is required.

15 Our findings favor use of an adjuvant over a neoadjuvant approach, without any increase in long-term

16 xic drugs broadly employed in pre-operative (neoadjuvant) breast cancer therapy, taxanes and anthracy

17 sigmoidoscopy for response assessment after neoadjuvant (chemo)radiotherapy between January 2012 and

18 n of a clinical complete response (CR) after neoadjuvant (chemo)radiotherapy.

19 Neoadjuvant chemoimmunotherapy could change the percepti

20 assess the antitumour activity and safety of neoadjuvant chemoimmunotherapy for resectable stage IIIA

21 y advanced rectal cancer (LARC) treated with neoadjuvant chemoradiation (NACR) enrolled in a phase II

22 Response to neoadjuvant chemoradiation (nCRT) has been debated as a

23 with complete clinical response (cCR) after neoadjuvant chemoradiation (nCRT) managed nonoperatively

24 ctal cancer patients which were treated with neoadjuvant chemoradiation enrolled in this study.

25 CT00072033, NCT00445861), which investigated neoadjuvant chemoradiation followed by surgery in patien

26 advanced rectal cancer patients treated with neoadjuvant chemoradiation followed by surgery.

27 thological complete response (pCR) following neoadjuvant chemoradiation for advanced pancreatic ducta

28 is marker predicted unfavorable responses to neoadjuvant chemoradiation in EAC patients.

29 ion of induction chemotherapy to concomitant neoadjuvant chemoradiation in locally advanced rectal ca

30 osatellite instability (MSI) and response to neoadjuvant chemoradiation in rectal cancer is not well

31 pCR for locally advanced rectal cancer after neoadjuvant chemoradiation in this NCDB-based analysis.

32 ed organoids to predict patient responses to neoadjuvant chemoradiation therapy, paving the way towar

33 locally advanced rectal cancer patients with neoadjuvant chemoradiation treatment.

34 ith respiratory comorbidity, tumor site, and neoadjuvant chemoradiation.

35 cases and was significantly associated with neoadjuvant chemoradiation.

36 (chemotherapy and 55.8 Gy radiotherapy), and neoadjuvant chemoradiotherapy (chemotherapy and 45 Gy ra

37 erapy (n=17), chemoradiotherapy (n=111), and neoadjuvant chemoradiotherapy (n=196).

38 ET(-CT) for detecting residual disease after neoadjuvant chemoradiotherapy (nCRT) for esophageal canc

39 ET/CT in response evaluations 12-14 wk after neoadjuvant chemoradiotherapy (nCRT) in esophageal cance

40 study of trastuzumab and pertuzumab added to neoadjuvant chemoradiotherapy (nCRT) in patients with EA

41 d a clinically complete response (cCR) after neoadjuvant chemoradiotherapy (nCRT) is being studied.

42 and clinically complete response (cCR) after neoadjuvant chemoradiotherapy (nCRT) undergoing active s

43 by the Mayo Clinic, multimodal therapy with neoadjuvant chemoradiotherapy and orthotopic liver trans

44 nd identified patients with EAC treated with neoadjuvant chemoradiotherapy followed by esophagectomy

45 esophageal adenocarcinoma (EAC) treated with neoadjuvant chemoradiotherapy followed by esophagectomy.

46 Neoadjuvant chemoradiotherapy followed by liver transpla

47 Neoadjuvant chemoradiotherapy followed by surgery establ

48 plications that required surgery (all in the neoadjuvant chemoradiotherapy group).

49 dverse events (chemoradiotherapy group, n=2; neoadjuvant chemoradiotherapy group, n=7), including thr

50 the entire age spectrum, adding pazopanib to neoadjuvant chemoradiotherapy improved the rate of patho

51 on or consolidation chemotherapy to standard neoadjuvant chemoradiotherapy results in a higher pCR ra

52 (n = 2688 treated with TNT and n = 891 with neoadjuvant chemoradiotherapy therapy).

53 al cancer receiving either DCR (n = 5977) or neoadjuvant chemoradiotherapy with planned esophagectomy

54 py, or no neoadjuvant therapy (compared with neoadjuvant chemoradiotherapy), open surgery, and resect

55 After neoadjuvant chemoradiotherapy, pCR and ypT1aN0 were seen

56 entified in 50% of patients and 74% received neoadjuvant chemoradiotherapy.

57 association exists for patients treated with neoadjuvant chemoradiotherapy.

58 ge (T1-3, N0-2, M0) in patients who received neoadjuvant chemoradiotherapy.

59 ents with perihilar cholangiocarcinoma after neoadjuvant chemoradiotherapy.

60 who have a clinical complete response after neoadjuvant chemoradiotherapy.

61 ieve pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) and which will have resid

62 from two phase II clinical trials evaluating neoadjuvant chemotherapy (NAC) in PDAC.

63 Response to neoadjuvant chemotherapy (NAC) in triple negative breast

64 Pathologic downstaging (pDS) to neoadjuvant chemotherapy (NAC) is one of the most import

65 sist in predicting treatment response in the neoadjuvant chemotherapy (NAC) setting.

66 The mean tumour size before neoadjuvant chemotherapy (NAC) was 4.21 +/- 0.99 cm and

67 tween PTGS2 expression, celecoxib use during neoadjuvant chemotherapy (NAC), and both event-free surv

68 To elucidate the effects of neoadjuvant chemotherapy (NAC), we conduct whole transcr

69 associated with multi-drug resistance to the neoadjuvant chemotherapy (NAC).

70 CR) and recurrence-free survival (RFS) after neoadjuvant chemotherapy (NAC).

71 umor-immune interface at baseline and during neoadjuvant chemotherapy (NACT) in high-grade serous ova

72 esponse in breast cancer patients undergoing neoadjuvant chemotherapy (NCT).

73 predicted pathological complete responses to neoadjuvant chemotherapy (P < 0.001) with high expressio

74 ten recurs despite aggressive treatment with neoadjuvant chemotherapy and (radical) cystectomy.

75 lly advanced unresectable PDAC receiving SOC neoadjuvant chemotherapy and chemoradiation.

76 ase in the breast or axilla after completing neoadjuvant chemotherapy and HER2-targeted therapy were

77 of breast cancer response after one cycle of neoadjuvant chemotherapy and may improve response predic

78 tant high-risk feature, and an indicator for neoadjuvant chemotherapy and prognosis.

79 ave extensive residual invasive cancer after neoadjuvant chemotherapy are at a high risk of recurrenc

80 Predictive biomarkers for tumor response to neoadjuvant chemotherapy are needed in breast cancer.

81 hort of patients from 2011-2017 treated with neoadjuvant chemotherapy followed by chemoradiation and

82 Platinum-based neoadjuvant chemotherapy followed by delayed primary sur

83 omen recruited to ICON8 who were planned for neoadjuvant chemotherapy followed by DPS and had RECIST

84 sponses in patients receiving platinum-based neoadjuvant chemotherapy followed by DPS in the ICON8 tr

85 w-up was 29.5 months (IQR 15.6-54.3) for the neoadjuvant chemotherapy followed by DPS population.

86 in ICON8, of whom 779 (50%) were planned for neoadjuvant chemotherapy followed by DPS.

87 The current standard of care is neoadjuvant chemotherapy followed by radical cystectomy,

88 RECIST and GCIG CA125 responses to neoadjuvant chemotherapy for epithelial ovarian cancer s

89 ical trials evaluating patients treated with neoadjuvant chemotherapy in borderline-resectable and lo

90 luate cyclin E as a predictor of response to neoadjuvant chemotherapy in breast cancer.

91 f data exploring the benefits of adjuvant or neoadjuvant chemotherapy in the treatment of breast canc

92 receptor 2 (HER2) -targeting drugs added to neoadjuvant chemotherapy increased pathologic complete r

93 ctDNA detection at the end of neoadjuvant chemotherapy indicated significantly worse r

94 Although neoadjuvant chemotherapy is a standard component of brea

95 should remain the regimen to choose whenever neoadjuvant chemotherapy is used in patients with high-r

96 Neither neoadjuvant chemotherapy nor routine surgery is needed t

97 5 breast cancer patients with information on neoadjuvant chemotherapy responses.

98 d, phase 3 trials, evaluation of response to neoadjuvant chemotherapy using Response Evaluation Crite

99 and previous treatment (previous adjuvant or neoadjuvant chemotherapy vs none).

100 Neoadjuvant chemotherapy was administered to 577 patient

101 ction of additional lesions in women without neoadjuvant chemotherapy were compared.

102 The scheduling of surgery and use of neoadjuvant chemotherapy were determined by local multid

103 ents with a clinical complete response after neoadjuvant chemotherapy who have been managed by a watc

104 umstances, the AHOPCA II protocol introduced neoadjuvant chemotherapy with delayed enucleation.

105 l after immediate primary surgery, or before neoadjuvant chemotherapy with subsequent planned delayed

106 There were 84 (75.4%) patients who received neoadjuvant chemotherapy, 105 (89%) simultaneous venous

107 After one cycle of neoadjuvant chemotherapy, a 34% reduction in the (13)C-l

108 r who had a clinical complete response after neoadjuvant chemotherapy, and who were subsequently mana

109 ight loss, higher ASA-score, higher N-stage, neoadjuvant chemotherapy, or no neoadjuvant therapy (com

110 EBL were trans-anastomotic stent placement, neoadjuvant chemotherapy, pancreaticogastrostomy reconst

111 In patients without neoadjuvant chemotherapy, pathologic size of index malig

112 egative (n = 38) breast cancers who received neoadjuvant chemotherapy.

113 ith "M1" low tumors, or with the response to neoadjuvant chemotherapy.

114 195 patients undergoing PAR (48.7%) received neoadjuvant chemotherapy.

115 regular diet for 3 days prior to and during neoadjuvant chemotherapy.

116 t present with any pathologic response after neoadjuvant chemotherapy.

117 Cyclin E independently predicted response to neoadjuvant chemotherapy.

118 ing EVs of breast cancer patients undergoing neoadjuvant chemotherapy.

119 ving pathological complete response (pCR) to neoadjuvant chemotherapy.

120 10 mL), both administered every 3 weeks with neoadjuvant chemotherapy.

121 Our data do not support the routine use of neoadjuvant CHT and RP in patients with clinically local

122 o difference was seen in 3-year BPFS between neoadjuvant CHT plus RP and RP alone (0.89 v 0.84, respe

123 Neoadjuvant CHT was associated with improved overall BPF

124 d, high-risk PC were assigned to RP alone or neoadjuvant CHT with androgen deprivation plus docetaxel

125 ial safety, efficacy and biomarker data with neoadjuvant combination anti-PD-L1 plus anti-CTLA-4, whi

126 Neoadjuvant SC-TNT is an alternative to neoadjuvant CRT for rectal cancer.

127 nonmetastatic cT2N0 rectal cancer managed by neoadjuvant CRT were retrospectively reviewed.

128 more likely to develop complete response to neoadjuvant CRT.

129 l (OS) was determined from the initiation of neoadjuvant, disease-free survival (DFS) from the date o

130 se and immunological analyses after a single neoadjuvant dose can be used to predict clinical outcome

131 premenopausal women receiving letrozole for neoadjuvant endocrine therapy, OFS was achieved more qui

132 between resected BR/LA patients who received neoadjuvant FOLFIRINOX and upfront resected patients.

133 ancreatic ductal adenocarcinoma (PDAC) after neoadjuvant FOLFIRINOX, (2) which patients might benefit

134 Following neoadjuvant FOLFIRINOX, 141 patients were surgically exp

135 o an upfront resection group (n = 394) and a neoadjuvant group (n = 152).

136 16 mo pN0 vs. 10 mo pN1 P < 0.001), and the neoadjuvant group (pN0 21 mo vs. 11 mo pN1, P < 0.001).

137 DT for 6 months starting 4 months before RT (neoadjuvant group) or concurrent and adjuvant ADT for 6

138 P < 0.001 and 64% vs. 78%, P = 0.040 in the neoadjuvant group).

139 T arms of both trials were combined into the neoadjuvant group, and the arms receiving adjuvant ADT w

140 currence patterns between pN0 and pN1 in the neoadjuvant group, in which 68% recurred with distant me

141 Relative to the neoadjuvant group, the hazard ratio for the concurrent g

142 s measure to five breast tumors treated with neoadjuvant HER2-targeted therapy.

143 Neoadjuvant hormone therapy followed by RP in locally ad

144 A previously conducted neoadjuvant ICB trial in patients with melanoma showed v

145 ta sets for response assessment of STS under neoadjuvant ILP.

146 e histopathologic therapy response of STS to neoadjuvant ILP.

147 tive resection (with detailed videos of post-neoadjuvant imaging) to assess propensity for surgical e

148 Findings from neoadjuvant immunotherapy studies may reveal pathways, m

149 alidation.PurposeTo test the hypothesis that neoadjuvant inhibition of PI3K/mTOR/AKT signaling reduce

150 esent a single case from a clinical trial of neoadjuvant intense androgen deprivation therapy.

151 gic response of soft-tissue sarcoma (STS) to neoadjuvant isolated limb perfusion (ILP).

152 The pancreatic neoadjuvant Massachusetts-score (PANAMA-score) was compu

153 A two-step treatment regimen, beginning with neoadjuvant metformin+venetoclax to induce apoptosis and

154 , 432 patients were randomly assigned to the neoadjuvant (n = 215) or concurrent group (n = 217).

155 Neoadjuvant nivolumab resulted in enhanced expression of

156 Our results support the addition of neoadjuvant nivolumab to platinum-based chemotherapy in

157 ubcutaneously every 3-4 weeks, starting with neoadjuvant or adjuvant chemotherapy, for about 6 months

158 reast cancer or relapsed within 12 months of neoadjuvant or adjuvant chemotherapy.

159 t with the same class of chemotherapy in the neoadjuvant or adjuvant setting (yes or no).

160 The neoadjuvant or concurrent ADT arms of both trials were c

161 orial trial, included a random assignment of neoadjuvant or concurrent versus adjuvant short-term ADT

162 Ottawa 0101 randomly assigned patients to neoadjuvant or concurrent versus concurrent or adjuvant

163 97 patients with PDAC who had undergone post-neoadjuvant pancreatectomy at four hospitals.

164 Neoadjuvant PD-1 blockade was associated with upregulati

165 ating modern systemic therapy delivered in a neoadjuvant/perioperative format for resectable PDA.

166 redict pathologic complete response (pCR) to neoadjuvant pertuzumab and trastuzumab (PT).

167 In the neoadjuvant phase, grade 3-4 adverse events were balance

168 odsHCC tumor-bearing mice were randomized to neoadjuvant PI3K/mTOR inhibitor (BEZ235) or control grou

169 Neoadjuvant PI3K/mTOR/AKT inhibition reduces postablatio

170 phase II, open-label, adaptively randomized neoadjuvant platform trial that screens experimental the

171 This Review focuses on the development of neoadjuvant (presurgical) immunotherapy in the era of PD

172 Neoadjuvant radiation is standard of care for locally ad

173 Patients with neoadjuvant radiotherapy and chemotherapy and survival <

174 There was no significant association between neoadjuvant regimen and any secondary outcome.

175 iation (standard group) or the same standard neoadjuvant regimen combined with HAPa immunotherapy (ex

176 atin and nab-paclitaxel could be a potential neoadjuvant regimen for resectable non-small-cell lung c

177 Neoadjuvant regimen was also not associated with a diffe

178 Preferred neoadjuvant regimens for early-stage triple-negative bre

179 tical for assessing tumor regression in post-neoadjuvant resections for PDAC.

180 emonstrated a pretreatment immune signature (neoadjuvant response signature) that was associated with

181 Neoadjuvant SC-TNT is an alternative to neoadjuvant CRT

182 ne checkpoint therapy is being tested in the neoadjuvant setting for patients with localized urotheli

183 ve to be the first trial of anti-PD-1 in the neoadjuvant setting for resectable MCC.

184 ition of taselisib to endocrine therapy in a neoadjuvant setting is consistent with the clinical bene

185 travenous pertuzumab plus trastuzumab in the neoadjuvant setting with comparable total pathological c

186 In the adjuvant/neoadjuvant setting, data do not support the routine add

187 se in different scenarios, especially in the neoadjuvant setting.

188 use of CDK4/6 inhibitors in the adjuvant and neoadjuvant settings, thereby further expanding and refi

189 ete response (pCR) rates (ypT0/is, N0) after neoadjuvant single-agent cisplatin (CDDP) versus doxorub

190 Neoadjuvant single-agent oral talazoparib once per day f

191 Patients received neoadjuvant SOC chemotherapy (FOLFIRINOX or gemcitabine/

192 A literature review identified neoadjuvant studies, including clinical trials, real-wor

193 al pathology (ypN0) in patients treated with neoadjuvant systemic therapy (NST) for different breast

194 ng in breast cancer (BC) patients undergoing neoadjuvant systemic therapy (NST); however, clinical ev

195 b combined with standard-of-care adjuvant or neoadjuvant systemic therapy and locoregional treatments

196 We suggest that neoadjuvant systemic therapy should be considered as the

197 Neoadjuvant systemic treatment (NST) elicits a pathologi

198 early stage disease after the completion of neoadjuvant therapies and tumor resection as well as to

199 ation, particularly for advanced cancers and neoadjuvant therapies, require continued assessment.

200 were tumor biology (80%), time interval from neoadjuvant therapy (61%), risk of becoming unresectable

201 in, nodal status, bone resection, and use of neoadjuvant therapy (before exenteration) on survival wa

202 her N-stage, neoadjuvant chemotherapy, or no neoadjuvant therapy (compared with neoadjuvant chemoradi

203 AEG, 650 underwent radical surgery, 55% post-neoadjuvant therapy (NeoT).

204 osite ratios/scores showed correlations with neoadjuvant therapy (p < 0.001).

205 sis (pretx), after completion of all planned neoadjuvant therapy (preop), and after surgery (postop)

206 iterature on the treatment outcomes of total neoadjuvant therapy (TNT) on locally advanced rectal can

207 Exclusion criteria were neoadjuvant therapy and incomplete follow-up.

208 Primary tumor resection rates after neoadjuvant therapy and overall survival (OS) were the p

209 ent outcome in the group of patients without neoadjuvant therapy and serves as a prognostic factor in

210 id not differ between patients who underwent neoadjuvant therapy and upfront surgery (88% vs 84%, P =

211 yield was demonstrated in patients receiving neoadjuvant therapy followed by esophagectomy.

212 Neoadjuvant therapy followed by planned esophagectomy ap

213 However, for patients undergoing neoadjuvant therapy for locally advanced adenocarcinoma,

214 pproach has the potential to be an effective neoadjuvant therapy for pancreatic cancer patients.

215 The optimal neoadjuvant therapy for resectable pancreatic ductal ade

216 Pathologic complete response (pCR) following neoadjuvant therapy has been associated with improved ev

217 tion could be made for or against the use of neoadjuvant therapy in cutaneous melanoma.

218 Surgical resection of LAPC after neoadjuvant therapy is feasible in a highly selected coh

219 Neoadjuvant therapy is increasingly used to control loca

220 Neoadjuvant therapy is now an active area of research fo

221 e II/III) demonstrated that females received neoadjuvant therapy less frequently than males and had w

222 y selected patients with advanced iCCA after neoadjuvant therapy may benefit from LT under research p

223 Neoadjuvant therapy may improve survival; however, it do

224 In conclusion neoadjuvant therapy may offer benefit over surgery-first

225 ssess the effect of surgical resection after neoadjuvant therapy on patient outcomes.

226 For DP, female sex and the absence of neoadjuvant therapy predicted better TO rates (OR 1.38 [

227 eas patients with residual tumor cells after neoadjuvant therapy primarily experienced relapse within

228 Akt inhibitor MK-2206 combined with standard neoadjuvant therapy resulted in higher estimated pCR rat

229 er of LAPC patients who respond favorably to neoadjuvant therapy undergo surgical resection.

230 5-year AR survival for neoadjuvant therapy was 0.2069 (0.0323-0.3300) versus 0.

231 1-year survival AR for neoadjuvant therapy was 0.7969 (0.6061-0.9500) versus 0.

232 et analysis of only those patients receiving neoadjuvant therapy was also performed.

233 Neoadjuvant therapy was significantly (P=0.004) associat

234 ved standard taxane- and anthracycline-based neoadjuvant therapy without (control) or with oral MK-22

235 Following neoadjuvant therapy, 4 of 5 tumors were fluorescent; the

236 candidates for curative resection following neoadjuvant therapy, and recent reports of survival are

237 Enrolment, neoadjuvant therapy, and surgery have been completed; ad

238 tential to improve selection for surgery and neoadjuvant therapy, avoiding surgery in aggressive dise

239 ancer with positive lymph nodes benefit from neoadjuvant therapy, but limitations in current clinical

240 Following neoadjuvant therapy, normalization of CA19-9, rather tha

241 Total neoadjuvant therapy, or systemic induction chemotherapy

242 ed EFS/OS in patients with TNBC who received neoadjuvant therapy, regardless of pCR status.

243 Exclusion criteria were neoadjuvant therapy, vascular- and unrelated organ resec

244 of combination palbociclib plus letrozole as neoadjuvant therapy.

245 unresectable PDAC undergoing resection after neoadjuvant therapy.

246 20%), after a median duration of 5 months of neoadjuvant therapy.

247 ful in guiding treatment decisions regarding neoadjuvant therapy.

248 were willing to offer exploration following neoadjuvant therapy.

249 oesophageal junction treated with or without neoadjuvant therapy.

250 improve rectal cancer patient selection for neoadjuvant therapy.

251 nge) age of 63 (18-90) years; 78.1% received neoadjuvant therapy.

252 RI at 3 T at baseline and after one cycle of neoadjuvant therapy.

253 tumor location, histologic subtype, or prior neoadjuvant therapy.

254 ries of resection after patient selection by neoadjuvant therapy.

255 CA19-9 (DeltaCA19-9) after the completion of neoadjuvant therapy; 3) normalization (CA19-9 <35 U/dL)

256 ctomy for patients undergoing multimodality (neoadjuvant) therapy for adenocarcinoma of the esophagus

257 cancers before and 48-72 h after initiating neoadjuvant trastuzumab-based chemotherapy.

258 sponse rate of 100% across both adjuvant and neoadjuvant treated populations with an overall predicti

259 Subset analysis of neoadjuvant-treated patients demonstrated a survival ben

260 astasis in upfront resected patients, nor in neoadjuvant-treated patients.

261 atients who had poor local tumor response to neoadjuvant treatment (96 mL/min/100 g +/- 33 for ypT2-4

262 The cut point for high and low SII before neoadjuvant treatment and before surgery was calculated

263 evaluated the first site of recurrence after neoadjuvant treatment as locoregional (LR) or distant me

264 s had better RFS, supporting the practice of neoadjuvant treatment before LT.

265 t not in the group of patients that received neoadjuvant treatment before surgery.

266 with carboplatin and nab-paclitaxel given as neoadjuvant treatment before surgical resection.

267 econd trial, cetuximab was added to the same neoadjuvant treatment concomitant with induction chemoth

268 owed by doxorubicin plus cyclophosphamide as neoadjuvant treatment for early-stage TNBC.

269 Endocrine therapy-based neoadjuvant treatment for luminal breast cancer allows e

270 70% of the patients with a luminal CR after neoadjuvant treatment for rectal cancer can be identifie

271 lowed by epirubicin plus cyclophosphamide as neoadjuvant treatment in patients with primary breast ca

272 PAD after neoadjuvant treatment is safe.

273 n margin rates across the cohorts, impact of neoadjuvant treatment on survival, associated morbidity,

274 CE-MRI scans can improve early prediction of neoadjuvant treatment outcomes in locally advanced breas

275 The median duration of the neoadjuvant treatment period was 5.1 months.

276 rapeutic assessment as well as monitoring of neoadjuvant treatment strategies of STS.

277 zed trials have shown improved outcomes with neoadjuvant treatment strategies.

278 Investigate the association between neoadjuvant treatment strategy and perioperative complic

279 In patients with early-stage TNBC, neoadjuvant treatment with atezolizumab in combination w

280 on grade 3-4 adverse events occurring during neoadjuvant treatment with HER2-targeted therapy plus ch

281 Patients received neoadjuvant treatment with intravenous atezolizumab (120

282 Patients received neoadjuvant treatment with intravenous paclitaxel (200 m

283 had treatment-related adverse events during neoadjuvant treatment, and 14 (30%) had treatment-relate

284 on, which included all patients who received neoadjuvant treatment, and in the per-protocol populatio

285 tumor type, tumor location, clinical stage, neoadjuvant treatment, and the hospital of surgery.

286 ents who developed metastatic disease during neoadjuvant treatment, median survival was 10.5 months c

287 After completion of neoadjuvant treatment, patients underwent esophagectomy.

288 otion MRI were investigated with response to neoadjuvant treatment, progression-free survival, and ov

289 whom 46 patients were enrolled and received neoadjuvant treatment.

290 rrently have an established standard-of-care neoadjuvant treatment.

291 ll-survival in the group of patients without neoadjuvant treatment.

292 72) disease underwent tumor resection after neoadjuvant treatment.

293 ole surgical specimen, and had no history of neoadjuvant treatment.

294 ere we report on the first pilot combination neoadjuvant trial ( NCT02812420 ) with anti-PD-L1 (durva

295 , randomized phase II investigator-sponsored neoadjuvant trial with funding provided by Sanofi and Gl

296 Alignment and consistency of neoadjuvant trials will facilitate optimal data organisa

297 cheduling and length of induction period for neoadjuvant use of targeted agents remain unsolved and v

298 n of surgeons favoring exploration following neoadjuvant varied extensively across 5 vignettes of LAP

299 fied by extent of surgical cytoreduction and neoadjuvant versus adjuvant chemotherapy.

300 Our phase III trial compared neoadjuvant versus concurrent initiation of ADT in combi